Header Logo

Connection

Mark Pollack to Lipopolysaccharides

This is a "connection" page, showing publications Mark Pollack has written about Lipopolysaccharides.
Connection Strength

1.668
  1. Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14. Infect Immun. 2000 Mar; 68(3):1655-63.
    View in: PubMed
    Score: 0.178
  2. Dual effects of LPS antibodies on cellular uptake of LPS and LPS-induced proinflammatory functions. J Immunol. 1997 Oct 01; 159(7):3519-30.
    View in: PubMed
    Score: 0.151
  3. Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide. Infect Immun. 1995 Nov; 63(11):4481-8.
    View in: PubMed
    Score: 0.132
  4. Lipopolysaccharide (LPS)-specific monoclonal antibodies regulate LPS uptake and LPS-induced tumor necrosis factor-alpha responses by human monocytes. J Infect Dis. 1995 Sep; 172(3):794-804.
    View in: PubMed
    Score: 0.130
  5. Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06. Infect Immun. 1994 Apr; 62(4):1137-43.
    View in: PubMed
    Score: 0.118
  6. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity. J Infect Dis. 1992 Jan; 165(1):34-45.
    View in: PubMed
    Score: 0.101
  7. In vitro and in vivo functional activities of monoclonal antibodies reactive with Pseudomonas aeruginosa serogroup 6 lipopolysaccharides. Antibiot Chemother (1971). 1991; 44:163-71.
    View in: PubMed
    Score: 0.094
  8. Pharmacodynamic and protective properties of a murine lipopolysaccharide-specific monoclonal antibody in experimental Pseudomonas aeruginosa pneumonia in mice. Microbiol Immunol. 1991; 35(12):1131-41.
    View in: PubMed
    Score: 0.094
  9. Specificity and function of monoclonal antibodies reactive with discrete structural elements of bacterial lipopolysaccharide. Adv Exp Med Biol. 1990; 256:331-40.
    View in: PubMed
    Score: 0.088
  10. Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide. J Infect Dis. 1989 Feb; 159(2):168-88.
    View in: PubMed
    Score: 0.083
  11. Monoclonal antibodies that recognize epitopes in the core and lipid A region of lipopolysaccharides. Prog Clin Biol Res. 1988; 272:327-38.
    View in: PubMed
    Score: 0.077
  12. Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides. J Clin Invest. 1987 May; 79(5):1421-30.
    View in: PubMed
    Score: 0.073
  13. Clinical significance of serum antibody responses to exotoxin A and type-specific lipopolysaccharides in patients with Pseudomonas aeruginosa infections. Am J Med. 1983 Jun; 74(6):980-7.
    View in: PubMed
    Score: 0.056
  14. Antibacterial properties of Pseudomonas aeruginosa immunotype 1 lipopolysaccharide-specific monoclonal antibody (MAb) in a murine thigh infection model: combined effects of MAb and ceftazidime. Microbiol Immunol. 2000; 44(8):629-35.
    View in: PubMed
    Score: 0.044
  15. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest. 1979 Feb; 63(2):276-86.
    View in: PubMed
    Score: 0.041
  16. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Invest Ophthalmol Vis Sci. 1997 Jun; 38(7):1418-25.
    View in: PubMed
    Score: 0.037
  17. Distinct functional activities in canine septic shock of monoclonal antibodies specific for the O polysaccharide and core regions of Escherichia coli lipopolysaccharide. J Infect Dis. 1994 Mar; 169(3):553-61.
    View in: PubMed
    Score: 0.029
  18. Development of an anti-idiotype monoclonal antibody mimicking the structure of lipopolysaccharide (LPS) inner-core determinants. Microb Pathog. 1993 Aug; 15(2):103-20.
    View in: PubMed
    Score: 0.028
  19. Lipopolysaccharide heterogeneity in Escherichia coli J5 variants: analysis by flow cytometry. J Infect Dis. 1992 Oct; 166(4):803-11.
    View in: PubMed
    Score: 0.027
  20. Fluorescence-activated cell sorter analysis of binding by lipopolysaccharide-specific monoclonal antibodies to gram-negative bacteria. J Infect Dis. 1990 Jul; 162(1):148-55.
    View in: PubMed
    Score: 0.023
  21. Lipopolysaccharide (LPS)-reactive monoclonal antibodies fail to inhibit LPS-induced tumor necrosis factor secretion by mouse-derived macrophages. J Infect Dis. 1989 May; 159(5):872-80.
    View in: PubMed
    Score: 0.021
  22. Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide. Infect Immun. 1986 Sep; 53(3):656-62.
    View in: PubMed
    Score: 0.017
  23. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. J Clin Invest. 1983 Dec; 72(6):1874-81.
    View in: PubMed
    Score: 0.014
  24. Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother. 1993 Feb; 37(2):164-70.
    View in: PubMed
    Score: 0.007
  25. Circulating immune complexes in cystic fibrosis. Pediatr Res. 1980 Jun; 14(6):830-3.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.